VetStem, Inc. Announces New Chief Development Officer
Leading regenerative veterinary medicine company, VetStem, Inc., announces a new Chief Development Officer, Dr. Anne S. Hale.
Leading regenerative veterinary medicine company, VetStem, Inc., proudly announces the addition of Anne S. Hale, DVM. Dr. Hale will serve as the company’s Chief Development Officer to help bring new regenerative medicine products to the market. VetStem founder and CEO, Dr. Bob Harman, stated, “We are excited to have Dr. Hale join the team. She brings significant experience in product development and regulatory approval. We plan to tap into her vast knowledge and skillset to expand VetStem’s product offerings.”
Dr. Hale is a residency trained internal medicine veterinarian and has been part of the clinical community for over 30 years. After residency training, a comparative NIH fellowship in transfusion medicine led to the successful start up of Midwest Animal Blood Services, an internationally known veterinary blood bank. Her background in preclinical testing, translational application of veterinary products, and point of care biopharmaceutical development have led to successful patient side test kits and therapeutics for large and small animals. Dr. Hale stated, “I am excited to work on the next therapeutic paradigm shift for veterinary medicine."
As the first company to provide adipose derived stem cell services to veterinarians in the United States and Canada, VetStem has processed over 15,000 patient samples resulting in over 35,000 stem cell treatments for animals. VetStem Cell Therapy is primarily used for the treatment of orthopedic conditions such as osteoarthritis as well as injured tendons and ligaments in dogs, cats, and horses. In addition to domestic animals, VetStem has worked with multiple exotic animal organizations to provide stem cell therapy for several exotic species.